Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PEAK1 related, kinase-activating pseudokinase 1 (PRAG1)
- Target
- PRAG1
- Molecular classification
- Enzyme (Pseudokinase), Scaffold protein, Tyrosine protein kinase family member (inactive)
01
Overview
PEAK1 related, kinase-activating pseudokinase 1 (PRAG1) is a catalytically inactive member of the tyrosine protein kinase family that functions mainly as a scaffold protein. PRAG1 acts as an effector of the small GTPase RND2, stimulating RhoA activity and inhibiting nerve growth factor (NGF)-induced neurite outgrowth. It also promotes Src family kinase signaling by modulating CSK localization, thus affecting cell morphology and motility. PRAG1 operates as a critical coactivator of Notch signaling. While implicated in various signaling pathways and disease contexts such as cancer and epilepsy, it currently has no known direct drug interactions or established biomarker roles[1][2][7].
- Other names
- PragminSugen kinase 223SGK223SgK223PEAK2NACKPEAK1-related kinase-activating pseudokinase 1RND2 effector proteinPEAK family member 2tyrosine-protein kinase PRAG1inactive tyrosine-protein kinase PRAG1homolog of rat pragma of Rnd2
02
Biological functions
Signal transductionScaffold for signaling complexesRegulation of cell morphology and motilityEffector of RND2 GTPaseStimulation of RhoA activityCoactivation of Notch signaling
03
Disease associations
Cancer (modulation of cell motility and signaling)Generalized epilepsy with febrile seizures plus, type 6X-linked nephrolithiasis type I
Beyond the preview
Go deeper on PEAK1 related, kinase-activating pseudokinase 1 (PRAG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEAK1 related, kinase-activating pseudokinase 1 (PRAG1).